

## Case Report

# Liver Abscess due to *Streptococcus pneumoniae*: A Clinical Rarity

Srujana Mohanty<sup>1</sup> and Manas Kumar Panigrahi<sup>2</sup>

<sup>1</sup>Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar-751019, Odisha, India

<sup>2</sup>Department of Gastroenterology, All India Institute of Medical Sciences, Bhubaneswar-751019, Odisha, India

Correspondence should be addressed to Srujana Mohanty; [srujana\\_micro@yahoo.co.in](mailto:srujana_micro@yahoo.co.in)

Received 17 January 2020; Revised 13 May 2020; Accepted 18 May 2020; Published 2 June 2020

Academic Editor: Larry M. Bush

Copyright © 2020 Srujana Mohanty and Manas Kumar Panigrahi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We report a case of pyogenic liver abscess caused by a rare causative agent, *Streptococcus pneumoniae*. A 45-year-old man with underlying uncontrolled diabetes mellitus who had stopped taking his daily dose of insulin since the last 4 days, presented with pain in the abdominal area of one-day duration. Upon his admission to achieve diabetic control, a routine ultrasound examination of abdomen revealed incidentally, a large abscess in the left lobe of the liver with impending rupture. Culture of the ultrasound-guided liver aspirate pus yielded pure growth of a penicillin-susceptible *S. pneumoniae* isolate. After 4 weeks of parenteral ceftriaxone therapy along with intensive regimen for diabetic control, the liver abscess became resolved, and the patient improved and was discharged with no residual infection or recurrence at four months and at one-year follow-up. A review of relevant literature related to *S. pneumoniae* liver abscess revealed a mention of such entity only on 4 previous occasions. The present case highlights an important though rare manifestation of *S. pneumoniae* infection and emphasizes the need to establish an early diagnosis of *S. pneumoniae* infection for improved patient survival and favourable outcome.

## 1. Introduction

Pyogenic liver abscess (PLA) is an important clinical entity in the general population with a significant mortality rate in both developing and developed countries [1, 2]. It is a particularly serious infection that can prove fatal if not treated promptly. The annual incidence of PLA varies from 2.3 to 15.45 cases per 100,000 person-years and found more in men than in women [1–3]. Hepatobiliary causes such as cholelithiasis, cholangitis, and obstructive malignancy affecting the biliary tree, biliary strictures, or congenital anomalies account for approximately 40%–60% of PLAs [4, 5]. Other causes include perforated bowel or appendicitis, dental infections, systemic sepsis, infection of contiguous structures, ventriculoperitoneal shunt, blunt trauma, and foreign bodies [4, 5]. Cryptogenic origins sometimes account for up to 80% of cases [5].

The common causative agents implicated are *Streptococcus milleri*, *Klebsiella pneumoniae*, and *Escherichia coli* [1, 2, 5, 6]. *Streptococcus pneumoniae*, a gram-positive bacteria and a commensal nasopharyngeal flora, is a major

human pathogen responsible for millions of death and significantly more invasive infections each year worldwide [7]. However, it has been implicated as a causative agent of PLA extremely rare in the literature [8–11]. We report a case of pyogenic liver abscess due to *S. pneumoniae* in an adult patient, the timely recognition of which saved the patient from undergoing a potentially fatal course.

## 2. Case Report

A 45-year-old man with underlying uncontrolled diabetes mellitus, who had stopped taking his daily dose of insulin since the last 4 days, presented with pain in the right abdominal area of one-day duration. He had no fever or any other significant systemic symptoms. He was a known alcoholic, but he had stopped consuming alcohol since the last 4 months. He had no other relevant medical history, including hypertension, history of contact with tuberculosis, or any urinary or bowel complaints. He gave no history of dental extraction or dental manipulation, no surgical history, and no history of bronchoscopy or any respiratory tract

manipulation in the recent past. On admission to achieve diabetic control, physical examination revealed a thin-built man (body weight 49 kg) who was awake and oriented to time, place, and person but appeared lethargic and pale. Vital signs included a lowered body temperature of 36.5°C, blood pressure of 126/76 mmHg, pulse of 62/min, and a regular respiratory rate of 18/min. No evidence of dental caries, periodontitis, or any other oral lesions were found. Abdominal examination revealed a soft, nontender, and slightly distended abdomen with no apparent hepatomegaly or splenomegaly.

**2.1. Laboratory Investigations.** Blood tests revealed an elevated alanine aminotransferase level of 103 IU/L and slightly elevated aspartate aminotransferase level of 44 IU/L, but normal alkaline phosphatase level of 178 IU/L. Hemogram reports were within normal limits except slight leukocytosis with a total leucocyte count of  $11.1 \times 10^9/L$  (66% polymorphs, 21% lymphocytes, and 9% eosinophils), total red blood cell count of  $4.9 \times 10^{12}/L$ , platelet count of  $324 \times 10^9/L$ , and haemoglobin level of 129 g/L. Blood metabolic panel suggested an extremely poor diabetes control with a high random blood sugar level of 299 mg/dL, fasting blood glucose level of 234 mg/dL, and postprandial blood sugar level of 575 mg/dL. Serum electrolytes and other biochemical parameters were within normal limits. The patient tested negative for anti-HIV-1/2 antibodies, anti-HCV antibodies, and for Hepatitis B surface antigen. An ultrasonogram of the abdomen revealed a large well-defined hypoechoic lesion of size  $13.8 \times 11.6 \times 12$  cm, with dense internal echoes and debris in the left lobe of the liver suggestive of a large left-sided liver abscess with impending rupture. Pigtail catheterization carried out under local anaesthesia drained approximately 1000 ml of brownish yellow liquid pus, which was sent for routine microbiological investigations including Ziehl-Neelsen stain, wet-mount, and culture for bacteria and fungi (Figure 1(a)). Thereafter, cavity was irrigated, wound drainage was performed, and parenteral antibiotics (ceftriaxone, levofloxacin, and metronidazole) were administered to the patient empirically pending culture results. Simultaneously, glycemic control was optimized with insulin therapy.

Gram smear of the abscess drainage showed polymorphs with lanceolate-shaped Gram-positive cocci, lying in pairs, short chains, and small clusters (Figure 1(b)). The culture yielded pure growth of smooth, dome-shaped, and glistening alpha-haemolytic colonies on blood agar plates after overnight incubation at 37°C in 5–10% carbon dioxide, which on further incubation became flat with raised edges and central umbonation with carrom coin appearance (Figure 1(c)). No growth was observed on the MacConkey agar plate. The organism was catalase-negative, did not hydrolyse bile-esculin, was optochin sensitive, demonstrated bile solubility with 10% sodium deoxycholate solution, and was identified as *Streptococcus pneumoniae* [12].

Antimicrobial susceptibility testing using both disk diffusion and Etest (HiMedia, Mumbai, India) to determine, respectively, the zone diameter and minimum inhibitory

concentrations (MICs) of various antibiotics showed the isolate to be susceptible to penicillin, ceftriaxone, levofloxacin, ertapenem, meropenem, clindamycin, chloramphenicol, vancomycin, and linezolid and resistant to erythromycin, doxycycline, and trimethoprim/sulfamethoxazole (Figure 1(d)) [13]. The MICs ( $\mu\text{g/ml}$ ) of penicillin, ceftriaxone, ertapenem, meropenem, clindamycin, vancomycin, and linezolid were 0.023, 0.016, 0.012, 0.023, 0.023, 0.5, and 0.19, respectively. Other routine microbiological investigations including blood culture did not reveal any significant finding. Amoebic serology was negative. Ziehl-Neelsen stain did not reveal any acid-fast bacteria. Wet-mount examination showed no trophozoites of *Entamoeba histolytica* or any fungal element. Antibiotic therapy with parenteral ceftriaxone was continued and clinical and radiological improvement was noted after two weeks, with decrease of abdominal pain and significant resolution of abscess. Parenteral ceftriaxone was administered for a total duration of 4 weeks, after which the patient was discharged, with advice of a 2-week course of oral cefixime. Clinical examination at four months and one-year of follow-up revealed no recurrence of infection or any new serious bacterial infection.

### 3. Discussion

*S. pneumoniae* is a colonizer in the nasopharynx of the human respiratory tract with 40–95% of infants and 1–10% of adults being colonized at any time [7]. It is the leading cause of pneumonia in children and is responsible for 30% of pneumonia cases in adults [7, 14]. The mortality rate for pneumococcal pneumonia can reach 11–40% even in developed countries [14]. In addition, it is responsible for a high burden of invasive pneumococcal diseases (consisting majorly of meningitis, sepsis, and bacteremia) in the general population with an annual incidence ranging from 23/100,000 to 188/100,000 [15, 16]. On an average, there are 4,100 cases of meningitis, 12,000 of bacteremia, 500,000 of pneumonia, and 7 million cases of otitis media due to *S. pneumoniae* annually in the United States alone [7]. Very rarely, unusual clinical manifestations of invasive pneumococcal diseases have been reported in literature consisting of pancreatic and liver abscess, aortitis, endocarditis, endophthalmitis, inguinal adenitis, arthritis and other osteoarticular infections, testicular and tubo-ovarian abscess, necrotizing fasciitis, pleural effusion, pyopneumothorax, mediastinitis with chest wall abscess, and multiple brain abscess [9, 17–20].

A review of relevant literature related to *S. pneumoniae* liver abscess revealed a mention of such entity only on 4 previous occasions reported as an individual case report in a single instance [8] and occurrence of a single case as part of microbiological spectrum of liver abscess cases in 3 others [9–11]. Almost similar to the present case, Gilardi and Dellepiane have described a patient with underlying diabetes mellitus who presented with liver abscess as the first manifestation of pneumococcal invasive disease, without respiratory symptoms and had a successful outcome on treatment with percutaneous drainage and systemic




FIGURE 1: Liver aspirate showing (a) brownish yellow liquid pus and (b) Gram-positive cocci (GPC) arranged in pairs, short chains, and small clusters (1000x). (c) Growth of *S. pneumoniae* on blood agar plate and (d) susceptibility of *S. pneumoniae* to various antibiotics by the disc-diffusion test.

antibiotics [8]. Intra-abdominal abscesses such as liver abscesses generally develop as a result of abdominal surgery, intra-abdominal pathologies, or penetrating abdominal trauma [21, 22]. Rarely, abscesses can result from a distant focus of infection reaching the abdomen through infectious bacteremia, usually in individuals with poor oral hygiene or as a result of medical manipulation such as dental extraction, acupuncture, hemorrhoidectomy, or colonoscopy [22]. In the current patient, a careful history and subsequent clinical examination had revealed no evidence of any dental infection/caries, dental extraction or manipulation, no surgical history, and no history of bronchoscopy or any other respiratory tract manipulation in the recent past. The source of infection in the present case, thus, remains speculative similar to many other reports of PLAs where a definitive source of infection could not be determined. In a study, 80% of liver abscesses were cryptogenic in origin [5]. A notable feature of the present case was the absence of any significant systemic feature in the patient in the presence of a rapidly progressive and potentially fatal condition. The absence of systemic symptoms may perhaps be attributed to the immune dysfunction and impaired immune response, especially the reduction of cytokine responses such as interleukin-1 and interleukin-6, often seen in diabetic individuals [23].

As regards the antimicrobial susceptibility status, the Indian *S. pneumoniae* nonmeningeal isolates have largely retained their susceptibility to penicillin and third-generation cephalosporins with <1% of nonmeningeal

pneumococcal isolates demonstrating penicillin and cefotaxime nonsusceptibility in a prospective laboratory-based surveillance conducted between January 2007 and July 2017 [24]. In another study on children younger than 5 years of age, pneumococcal resistance to trimethoprim/sulfamethoxazole, erythromycin, chloramphenicol, and penicillin was seen in 66%, 37%, 9%, and 8% of all invasive pneumococcal isolates, respectively [25].

#### 4. Conclusion

Our report throws light on the occurrence of a clinically rare manifestation of a relatively commonly isolated pathogen, *S. pneumoniae*, in clinical samples. It is extremely important to establish an early diagnosis of *S. pneumoniae* infection for improved patient survival and favourable outcome. The correct identification of the pathogen was helpful in the timely resolution of infection following appropriate guided antimicrobial therapy. Therefore, clinicians must be able to recognize and manage unusual pneumococcal infections.

#### Data Availability

The data used to support the findings of this study are included within the article.

#### Conflicts of Interest

The authors declare that they have no conflicts of interest.



## Authors' Contributions

Srujana Mohanty provided substantial contribution to the conception and design of the study and contributed to the acquisition, analysis, and interpretation of data for the work, and drafted the manuscript. She gave the final approval of the version to be published. Manas Kumar Panigrahi was the treating physician and contributed to the acquisition, analysis, and interpretation of data for the study as well as critically revised the work for important intellectual content.

## References

- [1] G. G. Kaplan, D. B. Gregson, and K. B. Laupland, "Population-based study of the epidemiology of and the risk factors for pyogenic liver abscess," *Clinical Gastroenterology and Hepatology*, vol. 2, no. 11, pp. 1032–1038, 2004.
- [2] L. Meddings, R. P. Myers, J. Hubbard et al., "A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends," *American Journal of Gastroenterology*, vol. 105, no. 1, pp. 117–124, 2010.
- [3] Y.-C. Chen, C.-H. Lin, S.-N. Chang, and Z.-Y. Shi, "Epidemiology and clinical outcome of pyogenic liver abscess: an analysis from the national health insurance research database of Taiwan, 2000–2011," *Journal of Microbiology, Immunology and Infection*, vol. 49, no. 5, pp. 646–653, 2016.
- [4] J. Cherian, R. Singh, M. Varma, S. Vidyasagar, and C. Mukhopadhyay, "Community-acquired methicillin-resistant pyogenic liver abscess: a case report," *Journal of Investigative Medicine High Impact Case Reports*, vol. 4, no. 3, Article ID 2324709616660576, 2016.
- [5] Y.-L. Hsu, H.-C. Lin, T.-Y. Yen, T.-H. Hsieh, H.-M. Wei, and K.-P. Hwang, "Pyogenic liver abscess among children in a medical center in Central Taiwan," *Journal of Microbiology, Immunology and Infection*, vol. 48, no. 3, pp. 302–305, 2015.
- [6] T. C. Pang, T. Fung, J. Samra, T. J. Hugh, and R. C. Smith, "Pyogenic liver abscess: an audit of 10 years' experience," *World Journal of Gastroenterology*, vol. 17, no. 12, pp. 1622–1630, 2011.
- [7] P. L. Wantuch and F. Y. Avci, "Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them," *Human Vaccines & Immunotherapeutics*, vol. 14, no. 9, pp. 2303–2309, 2018.
- [8] L. Gilardi and M. E. Dellepiane, "Absceso hepático como presentación inicial de la enfermedad invasora por *Streptococcus pneumoniae*," *Revista chilena de infectología*, vol. 28, no. 4, p. 381, 2011.
- [9] S. N. Taylor and C. V. Sanders, "Unusual manifestations of invasive pneumococcal infection," *The American Journal of Medicine*, vol. 107, no. 1A, pp. 12S–27S, 1999.
- [10] I. D. Ba, A. Ba, P. M. Faye et al., "Particularités des abcès du foie chez l'enfant au Sénégal: description d'une série de 26 cas," *Archives de Pédiatrie*, vol. 23, no. 5, pp. 491–496, 2016.
- [11] J. C. Moore-Gillon, S. J. Eykyn, and I. Phillips, "Microbiology of pyogenic liver abscess," *British Medical Journal*, vol. 283, no. 6295, pp. 819–821, 1981.
- [12] C. W. Winn, S. D. Allen, W. M. Janda et al., "Gram-positive cocci. Part II: Streptococci, Enterococci, and the "Streptococcus-like" bacteria," in *Koneman's color atlas and textbook of diagnostic microbiology*, G. W. Procop, D. L. Church, G. S. Hall et al., Eds., pp. 733–843, Wolters Kluwer Health, Philadelphia, PA, USA, 7th edition, 2017.
- [13] CLSI (Clinical and Laboratory Standards Institute), *Performance Standards for Antimicrobial Susceptibility Testing*, Clinical and Laboratory Standards Institute, Wayne, PA, USA, 28th edition, 2018.
- [14] C. C. Daniels, P. D. Rogers, and C. M. Shelton, "A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens," *The Journal of Pediatric Pharmacology and Therapeutics*, vol. 21, no. 1, pp. 27–35, 2016.
- [15] E. Backhaus, S. Berg, R. Andersson et al., "Epidemiology of invasive pneumococcal infections: manifestations, incidence, and case fatality rate correlated to age, gender, and risk factors," *BMC Infectious Diseases*, vol. 16, no. 1, p. 367, 2016.
- [16] C. G. Whitney, M. M. Farley, J. Hadler et al., "Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine," *New England Journal of Medicine*, vol. 348, no. 18, pp. 1737–1746, 2003.
- [17] M. C. Rodriguez Barradas, D. M. Musher, R. J. Hamill, M. Dowell, J. T. Bagwell, and C. V. Sanders, "Unusual manifestations of pneumococcal infection in human immunodeficiency virus-infected individuals: the past revisited," *Clinical Infectious Diseases*, vol. 14, no. 1, pp. 192–199, 1992.
- [18] P. Thaisiam and P. Rattanaumpawan, "Rare manifestations of *Streptococcus pneumoniae* infection; the first case report in Thailand and literature review of pneumococcal endophthalmitis and endocarditis," *Journal of the Medical Association of Thailand*, vol. 97, no. 12, pp. 1364–1369, 2014.
- [19] P. Ispahani, V. C. Weston, D. P. Turner, and F. E. Donald, "Septic arthritis due to *Streptococcus pneumoniae* in Nottingham, United Kingdom, 1985–1998," *Clinical Infectious Diseases*, vol. 29, no. 6, pp. 1450–1454, 1999.
- [20] A. Sousa, M. T. Pérez-Rodríguez, A. Nodar et al., "Clinical and microbiological characteristics of unusual manifestations of invasive pneumococcal disease," *Enfermedades Infecciosas Y Microbiología Clínica*, vol. 36, no. 5, pp. 284–289, 2018.
- [21] R. Simon and M. N. Swartz, "Peritonitis and intraabdominal abscesses," in *Infectious Diseases: The Clinician's Guide to Diagnosis, Treatment, and Prevention*, D. C. Dale, Ed., pp. 144–153, Web MB, New York, NY, USA, 2003.
- [22] S. Mohanty, M. K. Panigrahi, J. Turuk, and S. Dhal, "Liver abscess due to *Streptococcus constellatus* in an immunocompetent adult: a less known entity," *Journal of the National Medical Association*, vol. 110, no. 6, pp. 591–595, 2018.
- [23] S. E. Geerlings and A. I. Hoepelman, "Immune dysfunction in patients with diabetes mellitus (DM)," *FEMS Immunology & Medical Microbiology*, vol. 26, no. 3–4, pp. 259–265, 1999.
- [24] R. Jayaraman, R. Varghese, J. L. Kumar et al., "Invasive pneumococcal disease in Indian adults: 11 years' experience," *Journal of Microbiology, Immunology and Infection*, vol. 52, no. 5, pp. 736–742, 2019.
- [25] A. Manoharan, V. Manchanda, S. Balasubramanian et al., "Invasive pneumococcal disease in children aged younger than 5 years in India: a surveillance study," *The Lancet Infectious Diseases*, vol. 17, no. 3, pp. 305–312, 2017.